Revised Record date if 15 September 2026 has been fixed

Date: 12 August, 2026 The Secretary The Secretary BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Plot No. C/1. G Block Dalal Street Bandra -Kurla Complex, Bandra (East) Mumbai - 400 001 Mumbai- 400 051 Scrip Code: 544293 Scrip Symbol : SURAKSHA Dear Sir / Ma’am, Sub: Outcome of the Board meeting held today i.e. Wednesday, 12 August, 2026 Ref: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations’) as amended from time to time Pursuant to Regulation 30 read with Part A of Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’) as amended from time to time, we wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e. on Wednesday, 12 August, 2026, inter alia, considered and approved/ noted the following: 1. Approved the unaudited financial results (standalone and consolidated) of the Company for the quarter ended 30 June, 2026 and the same is enclosed along with the Limited Review Report issued by the Statutory Auditors of the Company, pursuant to Regulation 33 of SEBI Listing Regulations marked as “Annexure-A”; 2. Based on the recommendation of the Nomination and Remuneration Committee and the Audit Committee, appointment of Mr. Dinesh Gupta as the Chief Financial Officer of the Company with effect from 24 August 2026, who will also act as a Group Chief Financial Officer of the Company The details as required under Schedule III - Para A (7) of Part A of Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular dated January 30, 2026 is marked as “Annexure-B”; 3. Approved the revised Notice convening the 21st Annual General Meeting of the Company for the financial year 2025-26, to be held on Tuesday, 22 September 2026 through video conferencing/ other audio-visual means (‘VC/OAVM’). 4. Fixed Tuesday, 15 September 2026, as the Record Date, for the purpose of determining the entitlement of the shareholders to receive dividend for the financial year ended 31 March 2026. The dividend, if approved by the shareholders at the 21st AGM, shall be paid within the statutory period prescribed under the Companies Act, 2013. Suraksha Diagnostic Limited (Formerly known as Suraksha Diagnostic Private Limited) CIN: L85110WB2005PLC102265 Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata-700 156, West Bengal, India E-mail: investors@surakshanet.com I Website: www.surakshanet.com Phone:(033) 6605 9750 The aforesaid financial results are also being made available on the Company’s website at www.surakshanet.com. Please note that the meeting commenced at 03:00 P.M. (IST) and concluded at 04:30 P.M. (IST). You are requested to take the same on record. Thanking you. For Suraksha Diagnostic Limited Ritu Mittal Joint Managing Director & CEO DIN: 00165886 Encl.: as above Suraksha Diagnostic Limited (Formerly known as Suraksha Diagnostic Private Limited) CIN: L85110WB2005PLC102265 Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata-700 156, West Bengal, India E-mail: investors@surakshanet.com I Website: www.surakshanet.com Phone:(033) 6605 9750 Annexure A MSKA & Associates LLP l 1n 3f ti hn it Fy leB re , n Pc lh om tN. o*, . U Gn -1it ,8I 3 L0 o2 .l.EP 8GP (Formerty known as M S K A & Associates) xolk ta, w6t 8.ng.l 700 091 Chartered Accountants lndependent Auditor's Review Report on un.udited standalone ltnancial results of Suraksh. Diagnostic Limited for the quarter ended June 30, 2025 puBuant to tll€ Re8ulation 33 of the sEBl (Listin8 06ligatiorE and Dis.losure Requirements) Regulitions, 2015, as amended. To the 8o.rd of Director: of Sur.khi Di.gnGtic Limited 1 We ha\€ reviewed the accompanying statement of unaudited standatone financiat resutts of Suralsha oiagnostic Limited (hereinafter referred toas'the Compaoy')for the quarter ended June 30, 2026 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regutation 33 of the se.urities and Exchange Board ot lndia (Listing Obtigations and Di$tosure Requirements) Regutations, 2015, as amended (the Regutation:'). 2. This statemenr, which is rhe responsibitity of the company's lvlanagement and has been approved by the Company's Board of Directors, has been prepared in accorclan e with the recognition and measurement principLe! laid down in lndian Accounting Standard 34 'lnterim Finao.iat Reporting', prescribed under Section 133 of til€ Companies Act, 2013 ('the Act') read with relevant rules issued thereunder {'lnd AS 34') and other recognised accounting principte! generatty a.cepted in lndia and is in €omptian e with the Regulations. Our responsibility is to express a conctusion on the Statement based on our review. 3. We condEted our review of the Statement in accordance Mth the Standard on Review EngaSements (sRE) 2410, "Review of lnterim FinanciaL lnformation Performed by the lndepefldeflt Auditor ofthe Entity'issu€d by the lnstjtute of Chart€red accouotants of lndia. A review of interim financia( information consists of making inquiries, primariLy of persons responsibte for finan ial and accounting matters, and apptying anat),ticat and other review procedures. A review is sub*antiaLLy leis in xope than an audit conducted in accordance with standardson Auditing sp€cified mder section 143(10) of the Act and consequentty does mt enable us to obtain assuranae that we would become aware of att significant matters that might be identified in an audjt. A.cordingly, viE do not express an audit opinion. Based on our review conducted as stated in paragraph 3 above, nothjng has come to our attention that causes usto betieve that the accompanying Statement prepared in accordarre with rh€ recognition and measuremefit prirriples Laid &)wn in lnd AS 34 a nd other r€cognised accountjng principles generalty accepted in lndia has not disclosed the information required to be dirlosed in terms of the Regulations, iflctuding the manner in which it is to be dis.tosed, or that it.ontains any material mjsstatement. For M S K a & Associates LLP (Formerly known.s M 5 X A & A5sociat6) Chartered Accountants ICAIF tion No.105047W/W101187 embeBhiD No.: 061682 uon: %0(. 1682}TDN UY 8 S 03 (olkata Placer Date: 12 August 2026 n.silbrcd oflr.e 6ar, R h?j. Tibiu4 w6tdn E qa Hitmy! (tr€.8m (tudr, Nmb3i ,1606r, lkhartnra, ri6, ,,h Fn:bd I adEJn toEri*It' t€Lhd | tui'nb,lfp lcs l6rry.m rtlrd6.b.d I r..ni bbal lrmsl.Erzh Suraksha Clinic & Diagnostics surakshi Dl.Snortic Ltmtted Reg,stered Oltice : Plot no, DG-12/1, A.rion Area lD, Premiser rc, O2-0t27, Ne Town, RajarlEt, &tkata 7@156, Wet 86gal, tndra (ClN : 185110W82005P1C102265) Website I ww.surakshaft t..om Statement ol u..udlted itandalone fin.n.i.l rerulrr lor the quarter ended !0 June 2026 lO June 2026 I Rqenw tom ole6tion3 8,408.62 7,855.59 1,021.94 10,067.91 156 4r 110.28 109.57 475.71 4,565.03 7,945.41 30,501,1a Cost of materia8 .onsumed 1,003.18 868.80 1,610.01 Employe beneiit5 expenr5 1,185,26 1,123.23 1,241.44 5,167.00 167.d) 386,52 265.85 1,?tt.99 Depreciation and amortBatlon exp€nse 1,060.09 1,048.56 915.17 3,960,15 75.96 29.45 (89.04) 3,084,t2 3,119,21 2,672.93 't't,76J.n 6,910.15 5,425.19 75,741.61 l------1fr17 1,055.77 1,t12.08 4,171.41 vll Profit belore te (v-vr) 't,671,24 1,055,72 1,112.08 4,721.5'l Vlll lncome td exp€.$ Clrrcnt tax erpenE 4o7_97 219.11 285.67 1,0f2.82 (ii ) Tar penaining to earlier year I1.19 (iii) Defetred tax expense/(crcdt) 156.21) 145.49 41.54 -t42.47 Total tar expense (vrrD t3,1,30 127.21 1,r15.29 lX Profit lor the period/year (vll-vlll) 1,258.20 1,406,22 Othe. comprehe.rive in.ome (a) lteft that wlll not be re.l.ssified subsequently to prolit or lo$ (l) iemeasurement gain/(1o$) ofnet defined benefit plan 19,02 11.9f 26.00 76.@ (ii) hcome td elf4t on above t4.781 (9.55) (6.t4) (19.15) Othe. com [Showing first 8,000 characters — download PDF for full document]